" class="no-js "lang="en-US"> Alentis Therapeutics Archives - Medtech Alert
Friday, April 12, 2024

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Alentis Therapeutics, the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ […]

Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study

Alentis Therapeutics, the clinical-stage biotechnology company developing breakthrough treatments for organ fibrosis and CLDN1+ tumors, […]

Novo Holdings Invests in US$105 Million Series C Funding of Alentis Therapeutics

Novo Holdings A/S, a leading international life sciences investor, today announced it has participated in […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more